Avidity Biosciences Inc (RNA)

May 21, 2025, 4:05 PM EDT - 16 days ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 4:05 PM EDT - 4 weeks ago

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights

May 6, 2025, 9:00 AM EDT - 4 weeks ago

Avidity Biosciences to Participate in Upcoming Investor Conference

Apr 8, 2025, 9:00 AM EDT - 2 months ago

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Mar 31, 2025, 9:00 AM EDT - 2 months ago

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy

Mar 17, 2025, 7:00 AM EDT - 2 months ago

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial

Mar 12, 2025, 4:05 PM EDT - 3 months ago

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 28, 2025, 9:00 AM EST - 3 months ago

Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases

Feb 27, 2025, 4:05 PM EST - 3 months ago

Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights

Feb 25, 2025, 9:00 AM EST - 3 months ago

Avidity Biosciences to Participate in Upcoming Investor Conferences

Jan 8, 2025, 9:00 AM EST - 5 months ago

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025

Dec 11, 2024, 9:25 AM EST - 6 months ago

Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases

Nov 12, 2024, 7:00 AM EST - 7 months ago

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations

Nov 7, 2024, 4:05 PM EST - 7 months ago

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights

Oct 31, 2024, 9:00 AM EDT - 7 months ago

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024

Sep 24, 2024, 2:15 PM EDT - 9 months ago

Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases

Sep 5, 2024, 9:00 AM EDT - 9 months ago

Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month

Aug 27, 2024, 9:30 AM EDT - 10 months ago

Life Science Cares San Diego Scales Partnership with Avidity Biosciences Through Life Science Shares Program

Aug 19, 2024, 9:00 AM EDT - 10 months ago

Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Aug 16, 2024, 3:21 PM EDT - 10 months ago

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Aug 14, 2024, 8:30 PM EDT - 10 months ago

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

Aug 13, 2024, 4:01 PM EDT - 10 months ago

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Aug 9, 2024, 4:05 PM EDT - 10 months ago

Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 5, 2024, 9:00 AM EDT - 10 months ago

Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer

Jun 24, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

CTNM

Jun 20, 2024, 9:00 AM EDT - 1 year ago

Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day

Jun 17, 2024, 4:05 PM EDT - 1 year ago

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jun 13, 2024, 8:00 PM EDT - 1 year ago

Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock

Jun 12, 2024, 4:01 PM EDT - 1 year ago

Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock

Jun 12, 2024, 10:15 AM EDT - 1 year ago

Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday

CASY RTO

May 19, 2024, 11:23 AM EDT - 1 year ago

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

May 15, 2024, 9:00 AM EDT - 1 year ago

Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors

May 9, 2024, 4:05 PM EDT - 1 year ago

Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Feb 29, 2024, 1:39 PM EST - 1 year ago

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29, 2024, 12:00 PM EST - 1 year ago

Avidity Biosciences Honors Rare Disease Day®

Feb 29, 2024, 7:00 AM EST - 1 year ago

Avidity Biosciences Announces Oversubscribed $400 Million Private Placement

Feb 28, 2024, 4:05 PM EST - 1 year ago

Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights

Jan 5, 2024, 8:30 AM EST - 1 year ago

Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth

Nov 28, 2023, 7:43 AM EST - 1 year ago

Avidity Stock Soars on Collaboration Deal With Bristol Myers

BMY

Nov 28, 2023, 6:46 AM EST - 1 year ago

Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments

BMY

Nov 8, 2023, 4:05 PM EST - 1 year ago

Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights

Sep 26, 2023, 9:00 AM EDT - 1 year ago

Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society

Sep 7, 2023, 9:00 AM EDT - 1 year ago

Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs

Aug 31, 2023, 9:00 AM EDT - 1 year ago

Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference

Aug 8, 2023, 4:05 PM EDT - 1 year ago

Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights

Jul 10, 2023, 12:47 PM EDT - 2 years ago

Avidity Biosciences: Large Devaluation Of Stock Presents Opportunity

Jun 20, 2023, 9:00 AM EDT - 2 years ago

Avidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) Day

Jun 8, 2023, 9:00 AM EDT - 2 years ago

Avidity Biosciences Announces Upcoming Presentations at the 30th Annual FSHD Society International Research Congress

May 9, 2023, 4:05 PM EDT - 2 years ago

Avidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights

Apr 27, 2023, 3:40 PM EDT - 2 years ago

Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA™ Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1